Genmab A (GMAB) Long-Term Investments (2019 - 2026)

Genmab A has reported Long-Term Investments for 6 years, with the latest figure at $40.0 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 33.33% year-over-year to $40.0 million; the trailing twelve-month figure through Mar 2026 stood at $40.0 million (up 33.33% YoY), and the FY2025 full-year result was $37.0 million, up 15.62% from the prior year.
• Long-Term Investments for Q1 2026 stood at $40.0 million, up from $37.0 million in the prior quarter.
• The five-year high for Long-Term Investments was $40.0 million in Q1 2026, with the low at $20.0 million in Q4 2023.
• Historically, Long-Term Investments has averaged $32.9 million across 4 years, with a median of $35.0 million in 2025.
• Annual changes were most pronounced in 2024 — Long-Term Investments surged 60.0% — and 2025, when it rose 15.62%.
• Genmab A's Long-Term Investments stood at $20.0 million in 2023, then soared by 60.0% to $32.0 million in 2024, then climbed by 15.62% to $37.0 million in 2025, then climbed by 8.11% to $40.0 million in 2026.
• The last three Long-Term Investments figures came in at $40.0 million (Q1 2026), $37.0 million (Q4 2025), and $36.0 million (Q3 2025), per Business Quant data.